Overview

Dose Escalation Study of SH U04722 in Solid Tumors

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of SH U04722 in patients with solid tumor cancers. In addition, this study will identify the recommended dose and administration schedule of SH U04722 for phase II development in Japanese cancer patients, evaluate the pharmacokinetic profile of SH U04722 and gather preliminary data on the effectiveness of SH U04722 in patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer